VERA Vera Therapeutics, Inc. - 8-K

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 21, 2026, Vera Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of March 24, 2026, the record date for the Annual Meeting, 71,713,905 shares of Class A common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Each matter is described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 9, 2026 (the “Proxy Statement”).

Proposal 1– Election of Directors.

The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal. The final voting results are as follows:

Votes For

Votes Withheld

Broker Non-Votes

Michael M. Morrisey, Ph.D.

45,288,710

13,814,671

2,863,469

Patrick G. Enright

54,697,296

4,406,085

2,863,469

James R. Meyers

58,946,269

157,112

2,863,469

Proposal 2 – Ratification of the Appointment of Independent Registered Public Accounting Firm.

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The final voting results are as follows:

For

Against

Abstain

61,834,842

44,710

87,298

Proposal 3 – Advisory Vote on Executive Compensation.

The Company’s stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows:

For

Against

Abstain

Broker Non-Votes

56,585,568

2,433,537

84,276

2,863,469